To report a single-institutional experience with the use of orthovoltage radiation for head and neck non-melanoma cutaneous skin cancer (basal cell carcinoma – BCC, squamous cell carcinoma – SCC, and non-invasive squamous cell carcinoma – SCC in situ) and to compare outcomes by prescribed fractionation schedule.
D. Marconi, B. Resende, E. Rauber, P. Soares, J. Fernandes Junior, A. Carvalho, P. Kupelian & A. Chen.
Contact Us
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the AOCD 2024 meeting, in Scottsdale, AZ. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. Visit Xstrahl at AOCD 2024, booth # 22 at the Westin Kierland from April 11-14, 2024.
Xstrahl's Medical Director, Dr. Richard Shaffer, recently spoke for a webinar hosted by Joint Pain Practice. He shares how low-dose radiotherapy can be used for osteoarthritis, and overviews the treatment process, risks, and efficacy. https://youtu.be/ab4iyfhN_L8...
In this webinar, Tom Murray of Hull University Teaching Hospitals presents on developing an internal eye shield for radiotherapy. Internal eye shields are a simple yet effective solution to protect the patient’s lenses during superficial and orthovoltage radiation...
